Ongoing changes to the US H-1B visa programme are creating new challenges for biopharmaceutical companies seeking to attract and retain international talent. Rising sponsorship costs, a weighted selection system and additional proposed restrictions are prompting employers to reconsider how they recruit skilled workers.
The impact is particularly significant for startups and smaller biotechnology companies, which may have fewer resources to absorb substantial immigration costs. For businesses operating in highly specialised fields, these changes could also make it harder to recruit the expertise needed to advance research and development.
The fee has influenced hiring decisions, particularly among smaller employers that depend on international professionals but cannot easily absorb substantial additional costs.
The measure was extended through September 21, 2027, but legal challenges have resulted in federal court rulings blocking the fee. Its applicability should therefore be checked against the latest legal developments before employers make sponsorship decisions.
The uncertainty has already affected recruitment strategies. Some companies have shifted their attention towards candidates who are already authorised to work in the United States, including existing H-1B workers changing employers, US graduates, citizens and permanent residents.
For startups, the financial risk can be particularly difficult to justify when hiring early-career employees whose long-term immigration pathway remains uncertain.
This difference can affect access to international expertise in areas such as:
International candidates may also reconsider their options, including remaining in academia outside the United States rather than pursuing industry positions that require sponsorship.
Beginning in fiscal year 2027, the weighted selection system gives greater weight to registrations associated with higher wage levels. Under the framework described in the recent policy update, registrations at the lowest of four wage levels receive one entry into the selection pool, while those at the highest level receive four.
This may influence employers recruiting recent graduates and early-career professionals, whose salaries often fall below those of experienced specialists.
The Department of Labor has also proposed changes to how wage levels are calculated across several visa programmes, including H-1B. These changes could affect the wage classification associated with a position and, consequently, the number of entries it receives under the weighted selection system.
For biopharma employers, this creates another consideration when designing roles, setting compensation and planning sponsorship for international graduates.
In August 2026, the Department of Homeland Security proposed an additional $103,265 fee for H-1B cap-subject petitions, separate from the $100,000 fee discussed above.
The department also proposed changes to eligibility for H-1B cap exemptions, with greater scrutiny of employers that have violated programme requirements. Depending on the final rules, some research organisations that currently qualify for cap-exempt treatment could be affected.
These measures remain distinct from existing requirements and should not be treated as final rules merely because proposals have been announced.
The cumulative uncertainty nevertheless creates difficulties for employers planning recruitment several months or years in advance.
The figures demonstrate a substantial reduction in registrations, although they do not establish that any single policy change caused the decline.
For employers, the wider concern is how repeated changes affect recruitment decisions. Companies may become more cautious about sponsoring international candidates, particularly when a role is entry-level or the cost of sponsorship is difficult to predict.
Review recruitment strategies. Identify roles that depend on international expertise and assess where immigration uncertainty could affect hiring timelines.
Evaluate sponsorship costs early. Confirm the applicable fees and legal requirements before committing to a recruitment or sponsorship strategy.
Develop international talent pipelines. Build relationships with universities and identify qualified candidates early, while considering which candidates may already have suitable US work authorisation.
Review alternative immigration options. Depending on the position, employer and candidate, alternative visa classifications or cap-exempt pathways may be available.
Monitor legal and regulatory developments. Court decisions, proposed fees and changes to selection rules can affect sponsorship planning. Employers should verify the current requirements before acting.
The challenge for employers is finding ways to recruit the expertise they need while managing higher costs, legal uncertainty and longer hiring timelines.
Companies that develop domestic talent while maintaining flexible international recruitment strategies may be better positioned to address specialised workforce needs. However, continued restrictions could narrow the available candidate pool, especially for startups and businesses developing new technologies.
Ultimately, H-1B policy changes are becoming a strategic workforce consideration for the biopharma sector, affecting not only immigration compliance but also recruitment costs, research capacity and the ability to compete for highly specialised talent.
The impact is particularly significant for startups and smaller biotechnology companies, which may have fewer resources to absorb substantial immigration costs. For businesses operating in highly specialised fields, these changes could also make it harder to recruit the expertise needed to advance research and development.
The $100,000 H-1B Fee and Its Impact on Hiring
One of the most significant developments has been the introduction of a $100,000 fee for certain new H-1B petitions.The fee has influenced hiring decisions, particularly among smaller employers that depend on international professionals but cannot easily absorb substantial additional costs.
The measure was extended through September 21, 2027, but legal challenges have resulted in federal court rulings blocking the fee. Its applicability should therefore be checked against the latest legal developments before employers make sponsorship decisions.
The uncertainty has already affected recruitment strategies. Some companies have shifted their attention towards candidates who are already authorised to work in the United States, including existing H-1B workers changing employers, US graduates, citizens and permanent residents.
For startups, the financial risk can be particularly difficult to justify when hiring early-career employees whose long-term immigration pathway remains uncertain.
Why Startups and Smaller Biotechs Face Greater Pressure
Large pharmaceutical companies may have greater capacity to absorb exceptional recruitment costs when a particular specialist is essential to a project. Early-stage biotechnology companies often operate with tighter budgets and more limited hiring flexibility.This difference can affect access to international expertise in areas such as:
- Computational biology and artificial intelligence in drug discovery
- Cell and gene therapy
- Biostatistics
- Process development
- Research and development
International candidates may also reconsider their options, including remaining in academia outside the United States rather than pursuing industry positions that require sponsorship.
The Weighted H-1B Selection System
Immigration costs are not the only consideration. The H-1B selection process has also changed.Beginning in fiscal year 2027, the weighted selection system gives greater weight to registrations associated with higher wage levels. Under the framework described in the recent policy update, registrations at the lowest of four wage levels receive one entry into the selection pool, while those at the highest level receive four.
This may influence employers recruiting recent graduates and early-career professionals, whose salaries often fall below those of experienced specialists.
The Department of Labor has also proposed changes to how wage levels are calculated across several visa programmes, including H-1B. These changes could affect the wage classification associated with a position and, consequently, the number of entries it receives under the weighted selection system.
For biopharma employers, this creates another consideration when designing roles, setting compensation and planning sponsorship for international graduates.
Additional Proposed Restrictions
Other proposals could further affect hiring decisions.In August 2026, the Department of Homeland Security proposed an additional $103,265 fee for H-1B cap-subject petitions, separate from the $100,000 fee discussed above.
The department also proposed changes to eligibility for H-1B cap exemptions, with greater scrutiny of employers that have violated programme requirements. Depending on the final rules, some research organisations that currently qualify for cap-exempt treatment could be affected.
These measures remain distinct from existing requirements and should not be treated as final rules merely because proposals have been announced.
The cumulative uncertainty nevertheless creates difficulties for employers planning recruitment several months or years in advance.
A Changing Recruitment Landscape
USCIS reported that properly submitted H-1B registrations declined from 343,981 for fiscal year 2026 to 211,600 for fiscal year 2027, a decrease of approximately 38.5%.The figures demonstrate a substantial reduction in registrations, although they do not establish that any single policy change caused the decline.
For employers, the wider concern is how repeated changes affect recruitment decisions. Companies may become more cautious about sponsoring international candidates, particularly when a role is entry-level or the cost of sponsorship is difficult to predict.
What Biopharma Employers Should Do
Biopharmaceutical companies can take several practical steps to manage these challenges.Review recruitment strategies. Identify roles that depend on international expertise and assess where immigration uncertainty could affect hiring timelines.
Evaluate sponsorship costs early. Confirm the applicable fees and legal requirements before committing to a recruitment or sponsorship strategy.
Develop international talent pipelines. Build relationships with universities and identify qualified candidates early, while considering which candidates may already have suitable US work authorisation.
Review alternative immigration options. Depending on the position, employer and candidate, alternative visa classifications or cap-exempt pathways may be available.
Monitor legal and regulatory developments. Court decisions, proposed fees and changes to selection rules can affect sponsorship planning. Employers should verify the current requirements before acting.
Looking Ahead
Demand for specialist talent in biopharmaceutical research, manufacturing, quality and development is unlikely to disappear simply because immigration becomes more complex.The challenge for employers is finding ways to recruit the expertise they need while managing higher costs, legal uncertainty and longer hiring timelines.
Companies that develop domestic talent while maintaining flexible international recruitment strategies may be better positioned to address specialised workforce needs. However, continued restrictions could narrow the available candidate pool, especially for startups and businesses developing new technologies.
Ultimately, H-1B policy changes are becoming a strategic workforce consideration for the biopharma sector, affecting not only immigration compliance but also recruitment costs, research capacity and the ability to compete for highly specialised talent.
Pros and Cons Summary
Pros
- Employers may place greater emphasis on developing domestic talent and graduate recruitment.
- Early workforce planning can help businesses anticipate sponsorship costs and regulatory changes.
- Companies can assess alternative immigration routes where eligible.
- More structured recruitment planning may improve visibility over long-term staffing needs.
Cons
- High sponsorship costs may be prohibitive for startups and smaller biotechnology companies.
- Weighted selection may make sponsorship more challenging for some early-career professionals.
- Regulatory uncertainty can discourage employers from sponsoring international candidates.
- Scarce specialist roles may take longer to fill, potentially affecting research and development.
- Further proposed changes could increase complexity for employers and candidates.